ADVFN - Advanced Financial Network.
HOME» NYSE » M » MJN Stock Price » MJN Stock News

Morgan Stanley Dw Str Sat Att Share News

 Ms Dw Str Sat Att Stock Price
MJN Stock Price
 Ms Dw Str Sat Att Stock Chart
MJN Stock Chart
 Ms Dw Str Sat Att Stock News
MJN Stock News
 Ms Dw Str Sat Att Company Information
MJN Company Information
 Ms Dw Str Sat Att Stock Trades
MJN Stock Trades

Mead Johnson 4Q Profit Falls 14% On Higher Costs

DOW JONES NEWSWIRES Mead Johnson Nutrition Co.'s (MJN) fourth-quarter earnings fell 14% as the company was hit by higher commodities costs and operating expenses. For the new year, the company projected per-share earnings of $3 to $3.10, below recent estimates of analysts polled by Thomson Reuters for $3.18. The company has been focusing on growth in emerging markets, and unveiled plans for a $325 million manufacturing and technology center in Singapore last month. Sales in Asia and Latin America -- which represent about two-thirds of the company's topline -- were up 17%. In North American and Europe, sales were up 6%. Mead Johnson reported a profit of $85.6 million, or 42 cents a share, down from $99.6 million, or 48 cents a share, a year earlier. Excluding litigation and restructuring-related costs, earnings were down at 52 cents from 57 cents. The company in October expected per-share earnings of 51 cents. Revenue increased 14% to $911.3 million amid higher prices and as volume rose 11%. Analysts polled by Thomson Reuters recently expected $896 million. Gross margin eased to 61.1% from 62.3% amid higher commodities costs. Overhead costs rose 8.6% while advertising and promotion expenses were up 15%. Research and development costs were up 39%. The company was hit with a short-lived recall of a batch of powdered Enfamil baby formula last month after a baby in Missouri died from a rare bacterial infection. Early this month U.S. health regulators said tests of the formula showed no signs of contamination and some major retailers began returning the product to their shelves. Mead was spun off from drug maker Bristol-Myers Squibb Co. (BMY) in 2009, one of the largest such deals of the last two decades. Shares closed Wednesday at $72.60 and were inactive premarket. The stock has recovered about 5.6% since hitting a more than 9-month low when the recall was unveiled. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

Stock News for Morgan Stanley Dw Str Sat Att (MJN)
01/13/201716:50:25Current Report Filing (8-k)
01/03/201707:30:00Mead Johnson Schedules Fourth Quarter and Full Year 2016 Earnings...
12/14/201616:17:15Current Report Filing (8-k)
12/13/201616:30:00Mead Johnson Board of Directors Announces Dividend
11/15/201609:02:10Current Report Filing (8-k)
11/11/201617:49:00Mead Johnson to Present at the Morgan Stanley Global Consumer...
11/02/201612:11:01Statement of Changes in Beneficial Ownership (4)
11/01/201609:28:55Statement of Changes in Beneficial Ownership (4)
10/27/201607:51:44Quarterly Report (10-q)
10/27/201607:36:38Current Report Filing (8-k)
10/27/201607:30:00Mead Johnson Nutrition Reports Third Quarter & Nine Months 2016...
10/04/201615:03:33Statement of Changes in Beneficial Ownership (4)
10/03/201608:07:00Mead Johnson Schedules Third Quarter and Nine-Month 2016 Earnings...
09/08/201608:00:00Mead Johnson Board of Directors Announces Dividend
09/07/201608:32:06Current Report Filing (8-k)
08/31/201608:30:00Mead Johnson to Present at the Barclays Global Consumer Staples...
08/15/201616:49:50Statement of Changes in Beneficial Ownership (4)
08/05/201616:50:23Statement of Changes in Beneficial Ownership (4)
07/28/201608:02:33Quarterly Report (10-q)
07/28/201607:39:18Current Report Filing (8-k)

Morgan Stanley Dw Str Sat Att and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations